Gilead Sciences has entered into a licensing and collaboration agreement with South Korea’s Tuhan Corporation to co-develop novel therapeutic candidates for advanced fibrosis due to nonalcoholic steatohepatitis (NASH).
The agreement sees Gilead acquire global rights to develop and commercialise novel small molecules against two undisclosed targets in all countries (with the exception of the Republic of Korea where Yuhan will retain certain commercialisation rights).
The two companies will jointly conduct preclinical research, with Gilead responsible for global clinical development. Gilead will also be responsible for commercialisation worldwide, outside of Yuhan’s rights in the Republic of Korea.
Yuhan will receive an upfront payment of $15 million and is eligible to receive up to an additional $770 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on future net sales.
This agreement builds on the companies’ existing commercial collaboration to support the promotion of Gilead’s medicines in the Republic of Korea.
“This collaboration builds on our long-term partnership with Yuhan, with a new focus on the investigation of novel approaches to treat patients with advanced fibrosis due to NASH that complement our ongoing research programs,” said John McHutchison, Chief Scientific Officer and Head of Research and Development, Gilead Sciences.